Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia

Armando D’Angelo; Patrizia Della Valle; Annalisa Fattorini; Luciano Crippa

doi:10.1160/TH05-11-0722

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(03): 573-575
DOI: 10.1160/TH05-11-0722

Case Report

Schattauer GmbH

Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia

Authors

Armando D’Angelo

¹Servizio di Coagulazione ed Unita’ Ricerca Trombosi, IRCCS H. S. Raffaele, Milan, Italy
Patrizia Della Valle

¹Servizio di Coagulazione ed Unita’ Ricerca Trombosi, IRCCS H. S. Raffaele, Milan, Italy
Annalisa Fattorini

¹Servizio di Coagulazione ed Unita’ Ricerca Trombosi, IRCCS H. S. Raffaele, Milan, Italy
Luciano Crippa

¹Servizio di Coagulazione ed Unita’ Ricerca Trombosi, IRCCS H. S. Raffaele, Milan, Italy

Abstract

Full Text

References

References
1 Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-8.
2 Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The 7th ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 311S-337S.
3 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
4 Warkentin TE, Sheppard JI, Horsewood P. et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
5 Amiral J, Pouplard C, Vissac AM. et al. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol 2000; 109: 336-41.
6 Eichler P, Raschke R, Lubenow N. et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002; 116: 887-91.
7 Warkentin TE, Kelton JG. A 14-year study of heparininduced thrombocytopenia. Am J Med 1996; 101: 502-7.
8 Greinacher A, Volpel H, Janssens U. et al. for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia type II:a prospective study. Circulation 1999; 99: 73-80.
9 Fabris F, Luzzatto G, Soini B. et al. Risk factors for thrombosis in patients with immune mediated heparininduced thrombocytopenia. J Intern Med 2002; 252: 149-54.
10 Martel N, Lee J, Wells PS. Risk of heparin induced thrombocytopenia with unfractionated and low molecular weight heparin thromboprophylaxis: a metaanalysis. Blood 2005; 106: 2710-5.
11 Prandoni P, Siragusa S, Girolami B. et al., for the BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin. A prospective cohort study. Blood 2005; 106: 3049-54.
12 Girolami B, Prandoni P, Stefani PM. et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 2955-9.
13 Gruel Y, Pouplard C, Nguyen P. and the French Heparin-induced thrombocytopenia study group. Biological and clinical features of low-molecular weight heparin induced thrombocytopenia. Br J Haematol 2003; 121: 786-92.
14 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
15 Eichler P, Friesen H-J, Lubenow N. et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-8.
16 Greinacher A, Eichler P, Lubenow N. et al. Heparininduced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
17 The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
18 Buller HR, Davidson BL, Decousus H. et al. for the Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Ann Intern Med 2004; 140: 867-73.
19 Elalamy I, Lecrubier C, Potevin F. et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 1384-5.
20 Amiral J, Lormeau JC, Marfaing-Koka A. et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-7.
21 D’Amico EA, Villaca PR, Gualandro SF. et al. Successful use of Arixtra ina patient with paroxysmal nocturnal hemoglobinuria Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 2452-3.
22 Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005; 93: 999-1000.
23 Savi P, Chong BH, Greinacher A. et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-44.